A court in Belgium has ordered AstraZeneca to deliver additional doses of its COVID-19 vaccine to EU member states by 27 September, although far fewer than the amount sought by the European
CureVac has just had a harsh reminder of the perilous nature of drug development, after reporting that its mRNA-based COVID-19 vaccine was just 47% effective in its 40,000-subject phase 3 t
The delta variant of COVID-19 may be holding back the lifting of lockdown restrictions in the UK, but there is some good news – the AstraZeneca/Oxford University vaccine seems to offer a hi
The top-line phase 3 data for Novavax' COVID-19 vaccine look good, with a 90% overall efficacy rate, but a dip in its share price indicates investors fear it could be too late for the progr
The failings at a Baltimore, US factory making Johnson & Johnson's COVID-19 vaccine mean that millions of doses of the shot will have to be jettisoned, according to an FDA update.
Ocugen is the first company to be affected by the FDA's recent decision to raise the bar on emergency use authorisations for COVID-19 medicines, and will have to file for full approval of i
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.